Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin (2016 - 2025)

Enanta Pharmaceuticals' FCF Margin history spans 14 years, with the latest figure at 63.62% for Q4 2025.

  • For Q4 2025, FCF Margin rose 8702.0% year-over-year to 63.62%; the TTM value through Dec 2025 reached 27.57%, up 11779.0%, while the annual FY2025 figure was 49.24%, 9375.0% up from the prior year.
  • FCF Margin reached 63.62% in Q4 2025 per ENTA's latest filing, up from 118.94% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 149.57% in Q2 2025 to a low of 179.3% in Q1 2024.
  • Average FCF Margin over 5 years is 102.68%, with a median of 118.78% recorded in 2025.
  • Peak YoY movement for FCF Margin: crashed -11652bps in 2022, then surged 26819bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 49.31% in 2021, then crashed by -216bps to 155.69% in 2022, then grew by 9bps to 141.46% in 2023, then decreased by -6bps to 150.63% in 2024, then surged by 58bps to 63.62% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's FCF Margin are 63.62% (Q4 2025), 118.94% (Q3 2025), and 149.57% (Q2 2025).